Rheumatology.net

Rheumatology Xagena

Dermabase.it
XagenaNewsletter
Xagena Mappa
Medical Meeting

An update of the European League Against Rheumatism ( EULAR ) rheumatoid arthritis management recommendations to account for the most recent developments in the field, was released. An internationa ...


Filgotinib is JAK-1 selective catalytic inhibitor. Due to its target selectivity, Filgotinib is estimated to have a good efficacy and a better safety profile than unselective JAK inhibitors ( JAKi ). ...


Upadacitinib ( Rinvoq ) was developed as a JAK1-selective inhibitor by exploiting differences in the non-conserved domains outside the active sites of JAK1 and JAK2. In cellular assays, Upadacitinib ...


The SELECT‐EARLY trial studied the effect of Upadacitinib ( Rinvoq ), an oral, reversible, JAK inhibitor, as monotherapy in patients with predominantly early rheumatoid arthritis who are naïve or have ...


In phase 3 trials, Upadacitinib ( Rinvoq ), an oral JAK1-selective inhibitor, has been assessed as monotherapy versus Methotrexate ( SELECT-EARLY ) and in combination with Methotrexate versus Adalimum ...


Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with active systemic lupus erythematosus ( SLE ). The first phase 3 ...


Sodium glucose co-transporter 2 ( SGLT2 ) inhibitors reduce serum urate levels. In a post hoc analysis researchers have investigated the effect of Canagliflozin ( Invokana ) compared to placebo on gou ...


Allopurinol is commonly prescribed for gout, and its clinical use may expand with ongoing trials assessing its potential cardiorenal benefits. Because heart disease has been suggested to be a risk f ...


Objective of the study was to disentangle the role of nonsteroidal anti-inflammatory drugs ( NSAIDs ) in the increased risk of cardiovascular disease ( CVD ) among osteoarthritis patients. This lon ...


A study has compared efficacy and safety of subcutaneous Sarilumab ( Kevzara ) 200 mg and 150 mg every 2 weeks plus conventional synthetic disease-modifying antirheumatic drugs ( +csDMARDs ) versus o ...


Results from a phase 3 study evaluating Tanezumab 2.5 mg or 5 mg in patients with moderate-to-severe osteoarthritis ( OA ) pain were presented. Tanezumab 5 mg treatment arm met all three co-primary ...


A study presented at the Annual European Congress of Rheumatology ( EULAR 2018 ) has examined rates of malignancy in patients with rheumatoid arthritis ( RA ), excluding non-melanoma skin cancer ( NMS ...


Patients with systemic lupus erythematosus ( SLE ) are at risk of irreversible damage across multiple organ systems because of both active disease and medication toxicities. The severity and freque ...


Pain is one of the most important domains affecting health-related quality of life ( HRQoL ) in patients with psoriatic arthritis ( PsA ). Secukinumab ( Cosentyx ) has demonstrated rapid and sustain ...


Findings from two phase 3 studies, COAST-V and COAST-W, in adults with ankylosing spondylitis ( AS ), also referred to as radiographic axial spondyloarthritis ( axSpA ), were presented at the American ...